Diabetes patients usually focus on the impact of diabetes on the cardiovascular system, liver, and kidneys, but many are unaware of diabetic peripheral neuropathic pain (DPNP). Data shows that over 50% of diabetes patients experience DPNP.
Diabetic neuropathic pain is mainly caused by nerve damage due to chronic hyperglycemia in diabetes, affecting any part of the peripheral nervous system, including sensory, motor, and autonomic nerves. Patients may experience physical pain, insomnia, vivid dreams, anxiety, and other symptoms. The pain is described as stabbing, burning, tingling like ants crawling, numbness, freezing, or electric shock-like sensations. The pain is severe and persistent, significantly impacting patients' daily lives and work.
Traditional drugs for treating neuropathic pain often require dose titration due to various factors, starting with low doses and gradually increasing, which may lead to suboptimal dosing or other non-standard medication practices affecting efficacy.
Recently, at the annual meeting of the Pain Specialty Committee of the China Association of Chinese and Western Medicine in Suzhou, experts including Professor Li Shuiqing from Peking University Third Hospital shared research progress and results on the treatment of pain with cligabalin.
Cligabalin, developed by Haisco Pharmaceutical Group, is an innovative drug with independent intellectual property rights for treating neuropathic pain (NP). It is poised to become the world's first third-generation central nervous system calcium channel modulator that does not require dose titration.
